NLRP3 and COVID-19: Active NLRP3 inflammasome is present in peripheral blood mononuclear cells (PBMCs) and post-mortem tissues of COVID-19 patients, and high expression of its derived products such as Casp1p20 and IL-18 were seen to correlate with disease severity and poor clinical outcome (47).